Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer

P. Corradini, C. Voena, M. Astolfi, S. Dell'Oro, S. Pilotti, G. Arrigoni, M. Bregni, A. Pileri, A. M. Gianni

Research output: Contribution to journalArticle

Abstract

Background: This study evaluates the specificity of some reverse-transcriptase polymerase chain reaction (RT-PCR) assays for the detection of residual tumor cells in breast cancer patients. The following markers have been analysed: carcinoembryonic antigen (CEA), cytokeratins (CK19 and CK20), polymorphic epithelial mucin (MUC-1), epidermal growth factor receptor (EGFR), maspin, and mammaglobin. RT-PCR was employed to detect breast cancer cells in peripheral blood (PB), bone marrow (BM), and stem cell leukoaphereses (PBPC). Patients and methods: We evaluated the specificity of our RT-PCR assays on a panel of breast cancer specimens (n = 30), on PBPC in patients undergoing high-dose chemotherapy (n = 38), on BM (n = 7) and PB (n = 5) samples obtained from patients with breast cancer. Marrow cells, PB, and PBPC from normal subjects or hematological tumor patients were tested as negative controls. Results: Only maspin and mammaglobin met the criteria of sensitivity and specificity required for the detection of residual disease; they were expressed in 80% and 97% of breast cancer specimens, respectively, and not expressed in normal controls. CK19, CK20, EGFR, MUC-1, and CEA were sometimes expressed in normal blood cells and/or hematological tumors. Conclusions: Our data support the notion that maspin and mammaglobin are useful markers for RT-PCR detection of minimal residual disease (MRD) in breast cancer patients, and that perspective clinical studies are needed to determine wether RT-PCR assays will be useful in assessing prognosis, tailoring therapy, or developing new strategies for ex vivo purging.

Original languageEnglish
Pages (from-to)1693-1698
Number of pages6
JournalAnnals of Oncology
Volume12
Issue number12
DOIs
Publication statusPublished - 2001

Fingerprint

Residual Neoplasm
Reverse Transcriptase Polymerase Chain Reaction
Breast Neoplasms
Genes
Mucin-1
Carcinoembryonic Antigen
Epidermal Growth Factor Receptor
Blood Cells
Bone Marrow
Keratins
Bone Marrow Cells
SERPIN-B5
Neoplasms
Stem Cells
Drug Therapy
Sensitivity and Specificity

Keywords

  • Breast cancer
  • Mammaglobin
  • Maspin
  • Residual disease

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. / Corradini, P.; Voena, C.; Astolfi, M.; Dell'Oro, S.; Pilotti, S.; Arrigoni, G.; Bregni, M.; Pileri, A.; Gianni, A. M.

In: Annals of Oncology, Vol. 12, No. 12, 2001, p. 1693-1698.

Research output: Contribution to journalArticle

Corradini, P, Voena, C, Astolfi, M, Dell'Oro, S, Pilotti, S, Arrigoni, G, Bregni, M, Pileri, A & Gianni, AM 2001, 'Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer', Annals of Oncology, vol. 12, no. 12, pp. 1693-1698. https://doi.org/10.1023/A:1013573108945
Corradini, P. ; Voena, C. ; Astolfi, M. ; Dell'Oro, S. ; Pilotti, S. ; Arrigoni, G. ; Bregni, M. ; Pileri, A. ; Gianni, A. M. / Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer. In: Annals of Oncology. 2001 ; Vol. 12, No. 12. pp. 1693-1698.
@article{874cb275fd734faaa91a52582823c0ff,
title = "Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer",
abstract = "Background: This study evaluates the specificity of some reverse-transcriptase polymerase chain reaction (RT-PCR) assays for the detection of residual tumor cells in breast cancer patients. The following markers have been analysed: carcinoembryonic antigen (CEA), cytokeratins (CK19 and CK20), polymorphic epithelial mucin (MUC-1), epidermal growth factor receptor (EGFR), maspin, and mammaglobin. RT-PCR was employed to detect breast cancer cells in peripheral blood (PB), bone marrow (BM), and stem cell leukoaphereses (PBPC). Patients and methods: We evaluated the specificity of our RT-PCR assays on a panel of breast cancer specimens (n = 30), on PBPC in patients undergoing high-dose chemotherapy (n = 38), on BM (n = 7) and PB (n = 5) samples obtained from patients with breast cancer. Marrow cells, PB, and PBPC from normal subjects or hematological tumor patients were tested as negative controls. Results: Only maspin and mammaglobin met the criteria of sensitivity and specificity required for the detection of residual disease; they were expressed in 80{\%} and 97{\%} of breast cancer specimens, respectively, and not expressed in normal controls. CK19, CK20, EGFR, MUC-1, and CEA were sometimes expressed in normal blood cells and/or hematological tumors. Conclusions: Our data support the notion that maspin and mammaglobin are useful markers for RT-PCR detection of minimal residual disease (MRD) in breast cancer patients, and that perspective clinical studies are needed to determine wether RT-PCR assays will be useful in assessing prognosis, tailoring therapy, or developing new strategies for ex vivo purging.",
keywords = "Breast cancer, Mammaglobin, Maspin, Residual disease",
author = "P. Corradini and C. Voena and M. Astolfi and S. Dell'Oro and S. Pilotti and G. Arrigoni and M. Bregni and A. Pileri and Gianni, {A. M.}",
year = "2001",
doi = "10.1023/A:1013573108945",
language = "English",
volume = "12",
pages = "1693--1698",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "12",

}

TY - JOUR

T1 - Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer

AU - Corradini, P.

AU - Voena, C.

AU - Astolfi, M.

AU - Dell'Oro, S.

AU - Pilotti, S.

AU - Arrigoni, G.

AU - Bregni, M.

AU - Pileri, A.

AU - Gianni, A. M.

PY - 2001

Y1 - 2001

N2 - Background: This study evaluates the specificity of some reverse-transcriptase polymerase chain reaction (RT-PCR) assays for the detection of residual tumor cells in breast cancer patients. The following markers have been analysed: carcinoembryonic antigen (CEA), cytokeratins (CK19 and CK20), polymorphic epithelial mucin (MUC-1), epidermal growth factor receptor (EGFR), maspin, and mammaglobin. RT-PCR was employed to detect breast cancer cells in peripheral blood (PB), bone marrow (BM), and stem cell leukoaphereses (PBPC). Patients and methods: We evaluated the specificity of our RT-PCR assays on a panel of breast cancer specimens (n = 30), on PBPC in patients undergoing high-dose chemotherapy (n = 38), on BM (n = 7) and PB (n = 5) samples obtained from patients with breast cancer. Marrow cells, PB, and PBPC from normal subjects or hematological tumor patients were tested as negative controls. Results: Only maspin and mammaglobin met the criteria of sensitivity and specificity required for the detection of residual disease; they were expressed in 80% and 97% of breast cancer specimens, respectively, and not expressed in normal controls. CK19, CK20, EGFR, MUC-1, and CEA were sometimes expressed in normal blood cells and/or hematological tumors. Conclusions: Our data support the notion that maspin and mammaglobin are useful markers for RT-PCR detection of minimal residual disease (MRD) in breast cancer patients, and that perspective clinical studies are needed to determine wether RT-PCR assays will be useful in assessing prognosis, tailoring therapy, or developing new strategies for ex vivo purging.

AB - Background: This study evaluates the specificity of some reverse-transcriptase polymerase chain reaction (RT-PCR) assays for the detection of residual tumor cells in breast cancer patients. The following markers have been analysed: carcinoembryonic antigen (CEA), cytokeratins (CK19 and CK20), polymorphic epithelial mucin (MUC-1), epidermal growth factor receptor (EGFR), maspin, and mammaglobin. RT-PCR was employed to detect breast cancer cells in peripheral blood (PB), bone marrow (BM), and stem cell leukoaphereses (PBPC). Patients and methods: We evaluated the specificity of our RT-PCR assays on a panel of breast cancer specimens (n = 30), on PBPC in patients undergoing high-dose chemotherapy (n = 38), on BM (n = 7) and PB (n = 5) samples obtained from patients with breast cancer. Marrow cells, PB, and PBPC from normal subjects or hematological tumor patients were tested as negative controls. Results: Only maspin and mammaglobin met the criteria of sensitivity and specificity required for the detection of residual disease; they were expressed in 80% and 97% of breast cancer specimens, respectively, and not expressed in normal controls. CK19, CK20, EGFR, MUC-1, and CEA were sometimes expressed in normal blood cells and/or hematological tumors. Conclusions: Our data support the notion that maspin and mammaglobin are useful markers for RT-PCR detection of minimal residual disease (MRD) in breast cancer patients, and that perspective clinical studies are needed to determine wether RT-PCR assays will be useful in assessing prognosis, tailoring therapy, or developing new strategies for ex vivo purging.

KW - Breast cancer

KW - Mammaglobin

KW - Maspin

KW - Residual disease

UR - http://www.scopus.com/inward/record.url?scp=0035702477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035702477&partnerID=8YFLogxK

U2 - 10.1023/A:1013573108945

DO - 10.1023/A:1013573108945

M3 - Article

C2 - 11843246

AN - SCOPUS:0035702477

VL - 12

SP - 1693

EP - 1698

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 12

ER -